• Accurate 3-gene-signature for early diagnosis of liposarcoma progression 

      Serguienko, Anastassia; Braadland, Peder Rustøen; Meza-Zepeda, Leonardo A.; Bjerkehagen, Bodil; Myklebost, Ola (Journal article; Peer reviewed, 2020)
      Background Well- and dedifferentiated liposarcoma (WD/DDLPS) are rare mesenchymal malignant tumors that account for 20% of all sarcomas in adults. The WD form is a low-grade malignancy with a favourable prognosis which ...
    • Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour 

      Georgiesh, Tatiana; Namløs, Heidi Maria; Sharma, Nitin; Lorenz, Susanne; Myklebost, Ola; Bjerkehagen, Bodil; Meza-Zepeda, Leonardo A.; Boye, Kjetil (Journal article; Peer reviewed, 2021)
      Solitary fibrous tumour (SFT) is a mesenchymal neoplasm characterised by pathognomonic NAB2-STAT6 gene fusions. The clinical implications and prognostic value of different fusion variants has not been clarified. In the ...
    • Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma 

      Hanes, Robert; Munthe, Else; Grad, Iwona; Han, Jianhua; Karlsen, Ida Tveit; Mc Cormack, Emmet; Meza-Zepeda, Leonardo A.; Stratford, Eva Wessel; Myklebost, Ola (Peer reviewed; Journal article, 2019-02-21)
      Background: FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified FRS2, but we previously only demonstrated transient cytostatic effects when treating FRS2-amplified DDLPS ...
    • Rapid genome editing by CRISPR-Cas9-POLD3 fusion 

      Reint, Ganna; Li, Zhuokun; Labun, Kornel; Keskitalo, Salla; Soppa, Inkeri; Mamia, Katariina Aino Inkeri; Tolo, Eero; Szymanska, Monika; Meza-Zepeda, Leonardo A.; Lorenz, Susanne; Cieslar-Pobuda, Artur Grzegorz; Hu, Xian; Bodin, Diana L; Staerk, Judith; Valen, Eivind Dale; Schmierer, Bernhard; Varjosalo, Markku; Taipale, Jussi; Haapaniemi, Emma Maria (Journal article; Peer reviewed, 2021)
      Precision CRISPR gene editing relies on the cellular homology-directed DNA repair (HDR) to introduce custom DNA sequences to target sites. The HDR editing efficiency varies between cell types and genomic sites, and the ...